One number divided by the other shows the asymmetry directly. A trillion dollars a year spread over 400 million people is about $2,500 per affected person per year [1][2][1], and it recurs annually. The two large public research commitments described by Nature, $1.15 billion from the US government in December 2020 and Germany's 500 million euros, roughly $580 million, announced last year [5][6], sum to about $1.73 billion [2]. That is close to 0.17% of a single year's burden [3], or around $4.30 per affected person, spent once [4]. Chris Ponting, a geneticist at the University of Edinburgh, reads the shortfall as a ranking problem: these conditions are "not a priority, despite having a major destructive influence on our society" [15].
A tighter constraint sits underneath the money. Thousands of studies over six years have gone at mechanisms, cross-condition similarities and candidate treatments [16], and how an acute infection turns into a chronic illness is still unresolved, though many in the field think explanations are within reach [17]. Michael Peluso, an infectious-disease clinician at UC San Francisco, puts it as leads rather than answers [14]. What the community itself names as the main obstacle to treatment development is the absence of reliable disease markers [9]. That is a statement about trial design as much as about biology. RECOVER drew criticism for not testing enough treatments [7], and the deeper reason a cohort study cannot substitute for a trial is that it tells you who is sick and how they describe it, without handing you a quantity that moves when a drug works and holds still when it does not [6].
The same gap shapes the prevalence figures. Because no marker is validated, both the 6% and the 400 million rest on symptom-based case definitions rather than on a measured biological state [5], and neither figure, as reported, separates someone with residual breathlessness from someone who cannot leave the house [7].
The comparative history is what turns this into a testable design, beyond simple description. The English physician Thomas Dowse described lingering post-infection symptoms as post-influenza exhaustion in 1894, a few years after a respiratory epidemic [10]; post-polio syndrome, post-Ebola syndrome and post-treatment Lyme disease syndrome followed, with fatigue and neurological features recurring across them [11]. Amy Proal, who was diagnosed with ME/CFS a year after a 2004 infection and co-founded the research foundation PolyBio in 2018 [18], argues that almost every class of pathogen leaves a subset of people who do not recover [12]. That is a testable hypothesis, because it can fail: if the trigger biology turns out not to be shared, the common symptom label was the wrong unit of analysis, and pooled work across these conditions will surface that faster than any single cohort would.
My reading, with its condition stated: the field can design trials now, but it cannot yet power them. What is worth applying to the next wave of mechanism papers is a single test: whether the measurement replicates in a cohort somebody else assembled, for a different post-infection illness, without the original team in the room. Plausibility of the mechanism does not clear that bar on its own.
